Product Description
Ningetinib is a multi-target small molecule kinase inhibitor which can effectively inhibit multiple kinases such as VEGFR2, AXL, MER and c-Met. On the one hand, it can directly and indirectly inhibit the growth of tumor cells by blocking the formation of tumor blood vessels, and also plays an important role in tumor-related immune regulation. It has shown good preliminary efficacy and safety in NSCLC clinical trials. We believe that the combination therapy of CT053 and KN046 can achieve synergy and benefit more patients. (Sourced from: http://www.alphamabonc.com/en/html/news/2081.html)
Mechanisms of Action: TK Inhibitor, VEGFR2 Inhibitor, AXL Inhibitor, C-Met Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sunshine Lake Pharma
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Renal Cell Carcinoma|Small Cell Lung Cancer|Non-Small-Cell Lung Cancer
Phase 1: Acute Myeloid Leukemia|Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03125876 |
PCD-DCT053-16-002 | P1 |
Terminated |
Acute Myeloid Leukemia |
2019-08-19 |
50% |
2021-03-25 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date |
NCT04577703 |
PCD-DCT053-12-003 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2015-12-10 |
2020-10-08 |
Primary Endpoints|Treatments |
|
NCT04992858 |
CT053-NSCLC-201 | P2 |
Unknown status |
Non-Small-Cell Lung Cancer|Small Cell Lung Cancer |
2024-09-09 |
62% |
2024-12-12 |
Primary Endpoints|Treatments|Trial Status |
NCT03758287 |
PCD-DCT053-16-001 | P2 |
Unknown status |
Non-Small-Cell Lung Cancer |
2023-07-17 |
17% |
2024-06-04 |
Primary Endpoints|Treatments|Trial Status |
NCT03876925 |
PCD-DCT053-17-001 | P2 |
Terminated |
Renal Cell Carcinoma |
2020-03-01 |
16% |
2021-03-25 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |